A.R.T. Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

A.R.T. Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-493	Closed	-$66K	–	1491
2017 Q1	$66K	Buy	493 +157	+47%	+$23.1K	﹤0.01%	1312
2016 Q4	$53K	Buy	+336	New	+$64.4K	﹤0.01%	1212
2016 Q1	–	Sell	-170	Closed	-$239K	–	1438
2015 Q4	$239K	Buy	+170	New	+$296K	0.01%	1152
2015 Q2	–	Sell	-85	Closed	-$156K	–	1532
2015 Q1	$156K	Buy	+85	New	+$188K	0.01%	1272

Other funds holding ELDN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

A.R.T. Advisors's ELDN Position: Q2 2017 in Review

A.R.T. Advisors sold out of Eledon Pharmaceuticals (ELDN) in Q2 2017, closing a stake of 493 shares — an estimated $66K sold.

A.R.T. Advisors first reported a position in ELDN in Q1 2015 and held it in 4 quarters. The position peaked at $239K in Q4 2015. 19 funds tracked by Wall St. Rank hold ELDN as of Q2 2017.

A.R.T. Advisors reported no remaining Eledon Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
A.R.T. Advisors sold 493 Eledon Pharmaceuticals shares in Q2 2017, an estimated $66K.
A.R.T. Advisors first reported a position in Eledon Pharmaceuticals in Q1 2015 and held it in 4 quarters.
A.R.T. Advisors's Eledon Pharmaceuticals position peaked at $239K in Q4 2015.
19 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2017.

Based on A.R.T. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.